Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore, we elucidated the prevalence and clinical outcomes of hepatitis C in persons affected by leprosy in Sorokdo, Jeollanam-do, Korea. Methods: We retrospectively included 50 leprosy patients with positive hepatitis C virus (HCV) RNA test results (group A) hospitalized at the Sorokdo National Hospital from May 2016 to March 2018 and 73 patients with chronic hepatitis C who were treated with DAAs at the Chonnam National University Hospital (group B) from May 2016 to December 2017. Results: Overall, at the Sorokdo National Hospital, positive HCV antibody and HCV RNA rates were 18.4% and 11.0%, respectively. The mean participant age was 76.5±7 years, and 58% of participants were men. The genotypes were type 1b in 44% (22 out of 50) and type 2 in 56% (28 out of 50). Sustained virologic response was achieved at a rate of 95.5% (21/22) in genotype 1b and 92.9% (26/28) in genotype 2 patients. Ribavirin-induced hemolytic anemia occurred in 57.1% (16/28) of patients with genotype 2. Among these, 28.5% (8/28) received blood transfusions. Conclusions: Treatment efficacy was not different between the leprosy-affected population and the general population. However, severe ribavirin-induced hemolytic anemia requiring transfusion was present in 28.5% of genotype 2 patients. Therefore, we suggest ribavirin-free DAAs for the treatment of genotype 2 hepatitis C in leprosy-affected persons in the future.
Abstract
Background/Aims: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore, we elucidated the prevalence and clinical outcomes of hepatitis C in persons affected by leprosy in Sorokdo, Jeollanam-do, Korea. Methods: We retrospectively included 50 leprosy patients with positive hepatitis C virus (HCV) RNA test results (group A) hospitalized at the Sorokdo National Hospital from May 2016 to March 2018 and 73 patients with chronic hepatitis C who were treated with DAAs at the Chonnam National University Hospital (group B) from May 2016 to December 2017. Results: Overall, at the Sorokdo National Hospital, positive HCV antibody and HCV RNA rates were 18.4% and 11.0%, respectively. The mean participant age was 76.5±7 years, and 58% of participants were men. The genotypes were type 1b in 44% (22 out of 50) and type 2 in 56% (28 out of 50). Sustained virologic response was achieved at a rate of 95.5% (21/22) in genotype 1b and 92.9% (26/28) in genotype 2 patients. Ribavirin-induced hemolytic anemia occurred in 57.1% (16/28) of patients with genotype 2. Among these, 28.5% (8/28) received blood transfusions. Conclusions: Treatment efficacy was not different between the leprosy-affected population and the general population. However, severe ribavirin-induced hemolytic anemia requiring transfusion was present in 28.5% of genotype 2 patients. Therefore, we suggest ribavirin-free DAAs for the treatment of genotype 2 hepatitis C in leprosy-affected persons in the future.
참고문헌 (41)
- Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : a modelling study", Lancet Gastroenterol Hepatol, 2, pp.161~176 (2017)
- Hu KQ, "The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States", Hepatology, 29, pp.1311~1316 (1999)
- Fattovich G, "Morbidity and mortality in compensated cirrhosis type C : a retrospective follow-up study of 384 patients", Gastroenterology, 112, pp.463~472 (1997)
- Westbrook RH, "Natural history of hepatitis C", J Hepatol, 61, pp.S58~ (2014)[DOI]
- Petruzziello A, "Epidemiology of hepatitis B virus(HBV)and hepatitis C virus(HCV)related hepatocellular carcinoma", Open Virol J, 12, pp.26~32 (2018)
- Chung YS, "A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea", J Clin Virol, 106, pp.53~57 (2018)
- Sulkowski MS, "Anemia in the treatment of hepatitis C virus infection", Clin Infect Dis, 37, pp.S315~S322 (2003)
- Sulkowski MS, "Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection", J Viral Hepat, 11, pp.243~250 (2004)
- Bodenheimer HC Jr, "Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C : a multicenter trial", Hepatology, 26, pp.473~477 (1997)
- Weiss K, "Safety profile of interferon-alpha therapy", Semin Oncol, 25, pp.9~13 (1998)
- Fried MW, "Treatment of chronic hepatitis C infection with peginterferons plus ribavirin", Semin Liver Dis, 24, pp.47~54 (2004)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial", Lancet, 358, pp.958~965 (2001)
- Jong Eun Yeon, "Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD", IDSA and 2016 EASL, 2018, pp.24(3), 278~293[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Kim BK, "Current status of and strategies for hepatitis C control in South Korea", Clin Mol Hepatol, 23, pp.212~218 (2017)
- Suh DJ, "Current status of hepatitis C virus infection in Korea", Intervirology, 49, pp.70~75 (2006)
- 권근영, "Regional Distribution of Hepatitis C Virus Infection in the Republic of Korea, 2007-2011", Gut and Liver, 8(4), pp.428~432 (2014), 거트앤리버 소화기연관학회협의회
- 최재필, "한센병 병력자들의 C형간염: 유전자형 및 위험요인 연구", 대한내과학회지, 70(1), pp.11~16 (2006), 대한내과학회
- Choi SH, "The prevalence of hepatitis C virus infection in leprous patients", Korean J Gastroenterol, 30, pp.486~494 (1997)
- Choi SJ, "Status of hepatitis C of Hansen’s disease of Jeonbuk province", Korean Lepr Bull, 46, pp.63~72 (2013)
- Jung K, "A proposal for reforming the Hansen’s disease control policy", Ministry of Health and Welfare, ~ (2018)
- Guragain S, "Adverse reactions in leprosy patients who underwent dapsone multidrug therapy : a retrospective study", Clin Pharmacol, 9, pp.73~78 (2017)
- Deps P, "Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy", Lepr Rev, 83, pp.305~307 (2012)
- Egawa K, "Hepatitis C virus antibody, viral RNA and genotypes in leprous patients in Japan", J Hepatol, 24, pp.397~402 (1996)
- Tanaka M, "Survey of the antibody to HCV in National Leprosarium Suruga", Nihon Rai Gakkai Zasshi, 61, pp.88~91 (1992)
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea : a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- Nath I, "Immunology of leprosy and diagnostic challenges", Clin Dermatol, 33, pp.90~98 (2015)
- Fischer M, "Leprosy-an overview of clinical features, diagnosis, and treatment", J Dtsch Dermatol Ges, 15, pp.801~827 (2017)
- Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b : a multinational, phase 3, multicohort study", Lancet, 384, pp.1597~1605 (2014)
- McPhee F, "High Sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C Virus genotype 1b without baseline ns5a polymorphisms", Adv Ther, 32, pp.637~649 (2015)
- Kao JH, "All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus(HCV)genotype 1b infection : a sub-analysis in Asian patients from the HALLMARK DUAL study", Liver Int, 36, pp.1433~1441 (2016)
- Sarrazin C, "The importance of resistance to direct antiviral drugs in HCV infection in clinical practice", J Hepatol, 64, pp.486~504 (2016)
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
- Kao JH, "A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection", Liver Int, 36, pp.1101~1107 (2016)
- Young Min Kim, "Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study", Clinical and Molecular Hepatology, 24(3), pp.311~318 (2018), 대한간학회
- Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)
- Foster GR, "Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection", Gastroenterology, 149, pp.1462~1470 (2015)
- European Association for the Study of the Liver, "EASL recommendations on treatment of Hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- Takaki S, "Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C", J Gastroenterol, 39, pp.668~673 (2004)
- Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", N Engl J Med, 373, pp.2608~2617 (2015)
- Asselah T, "Efficacy of glecaprevir", pibrentasvir for 8 or 12 weeks in patients with hepatitis c virus genotype 2, 4, 5, or 6 infection without cirrhosis, 2018, pp.16, 417~426